Weed (BUDZ) Cost of Revenue (2022)

Weed's (BUDZ) quarterly Cost of Revenue came in at -$2230.0 in Q4 2022, down 200.0% quarter-over-quarter from $2230.0 in Q3 2022.

Weed (BUDZ) Cost of Revenue (2022) Analysis & Trends

Weed's Cost of Revenue history runs 1 years deep, the most recent figure standing at -$2230.0 for Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cost of Rev (Qtr)
1	Haleon	89.28 Bn	87.42 Bn	-	-
2	Teva Pharmaceutical Industries	35.97 Bn	32.23 Bn	1.97 Bn	2.01 Bn
3	Zoetis	32.42 Bn	30.48 Bn	1.62 Bn	641.00 Mn
4	Takeda Pharmaceutical	27.48 Bn	23.42 Bn	4.39 Bn	2.59 Bn
5	United Therapeutics	22.89 Bn	20.73 Bn	648.10 Mn	133.40 Mn
6	RedHill Biopharma	22.11 Bn	22.11 Bn	-	-
7	Viatris	20.44 Bn	18.64 Bn	1.16 Bn	2.36 Bn
8	Neurocrine Biosciences	17.76 Bn	16.44 Bn	800.70 Mn	13.80 Mn
9	Elanco Animal Health	12.62 Bn	12.19 Bn	785.00 Mn	586.00 Mn
10	Weed	3.10 Mn	3.10 Mn	-	-

Download Data